Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function

Kidney International

Volumn 73, Issue 2, 2008, Pages 200-206

  Fan, S L S ^a,b   Pile, T ^a   Punzalan, S ^a   Raftery, M J ^a   Yaqoob, M M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Creatinine clearance; End stage renal failure; Peritoneal dialysis; Peritoneal membrane; Randomized controlled trials

Indexed keywords

CREATININE; UREA;

ADULT; ARTICLE; BODY SURFACE; COMORBIDITY; CREATININE CLEARANCE; DEMOGRAPHY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; URINALYSIS;

EID: 37549066703     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002574     Document Type: Article

References (20)

1. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant 1907; 17(Suppl 3): 12-15.
2. Park MS, Kim JK, Holmes C, Weiss MF. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int 2000; 20(Suppl 5): S33-S38.
3. Ha H, Yu MR, Choi HN et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 2000; 20(Suppl 5): S10-S18.
4. Boulanger E, Wautier MP, Gane P et al. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004; 19: 2208-2216.
5. Skoufos L, Topley N, Cooker L et al. The in vitro biocompatibility performance of a 25 mmol/l bicarbonate/10 mmol/l lactate-buffered peritoneal dialysis fluid. Kidney Int Suppl 2003; 88: S94-S99.
6. Sundaram S, Cendoroglo M, Cooker LA et al. Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis 1997; 30: 680-689.
7. Lee HY, Choi HY, Park HC et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21: 2893-2899.
8. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255.
9. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
10. Williams JD, Topley N, Craig KJ, et al., On behalf of The Euro-Balance Trial. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
11. Bargman JM. Peritoneal dialysis solutions and patient survival: does wishing make it so? Nephrol Dial Transplant 2006; 21: 2684-2686.
12. Blunden M, Zeitlin D, Ashman N, Fan SL. Single UK centre experience on the treatment of PD peritonitis - antibiotic levels and outcomes. Nephrol Dial Transplant 2007; 22: 1714-1719.
13. Szeto CC, Chow KM, Lam CW et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products - a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559.
14. Paniagua R, Frias Y, de Ventura MJ et al. C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. Perit Dial Int 2003; 23: 132-137.
15. Kumar S, Raftery M, Yaqoob M, Fan SL. Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 2007; 27: 283-287.
16. Mackenzie R, Holmes CJ, Jones S et al. Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney Int Suppl 2003; 88: S84-S93.
17. Jorres A, Bender TO, Finn A et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54: 2184-2193.
18. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357.
19. Simonsen O, Wieslander A, Landgren C, Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. Adv Perit Dial 1996; 12: 156-160.
20. Haas S, Schmitt CP, Arbeiter K et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14: 2632-2638.